Recent studies show that INC is characterized by distinct CKD stage-dependent abnormalities in bone metabolism, including sclerostin and FGF23, which differs markedly to that observed in patients with other underlying causes of CKD as outlined below [13,14]. Here, FGF23 is linked to chronic kidney disease.